Source: Cailian
"Science and Technology Innovation Board Daily", October 5: Neuralink, a brain-computer interface company owned by Musk, submitted its first human research data to a peer-reviewed journal, an important step towards scientific transparency.
According to media news on October 5, Michael Lawton, CEO and President of the Barrow Neurological Institute, Neuralink's clinical trial base, revealed that Neuralink has submitted the first academic paper containing its human trial safety data to the New England Journal of Medicine, introducing the latest status of its first three subjects, including surgical safety data.
Lawton discussed the paper at a brain implant conference hosted by Mount Sinai Health System in New York, but declined to disclose further details of the findings.
Lawton noted that Neuralink’s program still focuses on patients with severe disabilities.He said the company has a “long way to go” from implanting the device into healthy individuals.DJ Seo, president of Neuralink, said in September that the company’s goal is to this by 2030.
Founded in 2016, Neuralink focuses on developing high bandwidth, micro-traumatic brain-computer interfaces with the aim of enabling direct communication between the human brain and the computer. In June this year, Neuralink announced the completion of an E round of $6.5 billion, and the company’s valuation jumped to $9 billion.
On September 9, local time, the company announced that 12 people around the world had undergone the N1 brain computer chip implantation test developed by it. These patients had used its device for a total of 2000 days, and the cumulative use time exceeded 15000 hours. In addition to brain-computer interfaces for digital control, Neuralink is also exploring technologies to restore vision, interpret speech directly from brain activity, and treat neurological diseases such as Parkinson's disease.
Previously, Neuralink had never published peer-reviewed human trial data. According to media reports, other research groups and companies have already publicly shared similar research results, facilitating scientific evaluation and cooperation.